Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents

7Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

The number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation–response, mutation–non-response, or mutation–relapse patterns. The aim of this review is to provide a concise overview of the current state of knowledge with respect to newly approved AML treatment options and the association of response, relapse and resistance with genetic alterations. Specifically, we will highlight current genetic data regarding FLT3 inhibitors, IDH inhibitors, hypomethylating agents (HMA), the BCL-2 inhibitor venetoclax (VEN), the anti-CD33 antibody conjugate gemtuzumab ozogamicin (GO) and the liposomal dual drug CPX-351.

Cite

CITATION STYLE

APA

Halik, A., Arends, C. M., Bullinger, L., Damm, F., & Frick, M. (2022, April 1). Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents. Cancers. MDPI. https://doi.org/10.3390/cancers14071689

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free